Pediatric migraine: Neurodevelopmental mechanisms, clinical phenotypes, and modern therapeutics

Abstract

Migraine is among the most prevalent neurological disorders in children and adolescents and is a leading cause of functional disability, school absenteeism, and impaired quality of life. Pediatric migraine is not merely a younger manifestation of the adult disease; rather, it exhibits distinct clinical phenotypes, developmental neurobiology, triggers, and treatment responses. The growing recognition of its long-term burden underscores the need for updated, pediatric-focused, evidence-based guidance. This narrative review synthesizes contemporary evidence on pediatric migraine across the lifespan, integrating epidemiology, genetic susceptibility, and age-dependent neurobiological mechanisms. Key clinical features, including migraine equivalents and episodic syndromes associated with migraine, are discussed alongside diagnostic considerations using the International Classification of Headache Disorders, third edition, and validated pediatric disability assessment tools. Acute and preventive management strategies are reviewed in detail, encompassing optimized use of non-steroidal anti-inflammatory drugs and triptans, antiemetics, nerve blocks, neuromodulation devices, and emerging targeted therapies such as calcitonin gene-related peptide monoclonal antibodies and gepants. Evidence-based non-pharmacological interventions, including lifestyle optimization, sleep hygiene, cognitive-behavioral therapy, and comorbidity management, are also integral components of care. Pediatric migraine should be recognized as a chronic, neurodevelopmentally modulated neurological disorder that warrants early diagnosis and a multimodal, individualized treatment approach. Advances in mechanistic understanding, neurostimulation technologies, and targeted biologic therapies are reshaping the therapeutic landscape and hold promise for more precise and effective migraine management in children and adolescents.

Key Words: Pediatric migraine; Episodic syndromes; Migraine equivalents; Diagnosis; Neuromodulation devices; Calcitonin gene-related peptide monoclonal antibodies; Gepants

Core Tip: Pediatric migraine is a common yet underrecognized neurodevelopmental disorder with age-specific clinical phenotypes, mechanisms, and treatment responses. Children are not “small adults”; migraine expression evolves with brain maturation, hormonal changes, and sensory processing, necessitating pediatric-specific diagnostic and therapeutic strategies. Early recognition of migraine equivalents, timely access to acute treatment, and avoidance of medication overuse are essential to prevent chronification. While traditional preventives offer limited efficacy, emerging mechanism-based therapies and neuromodulation devices are reshaping care. A multimodal, individualized approach integrating pharmacologic, behavioral, and educational interventions is critical to improving long-term outcomes.

INTRODUCTION

Migraine is not merely a severe episodic headache but a complex, genetically mediated neurobiological disorder characterized by altered sensory processing, dysregulated pain modulation, and abnormal neurovascular signaling. It represents one of the leading causes of disability among children and adolescents worldwide, with consequences that extend well beyond the ictal period[1]. Despite its high prevalence and substantial burden, pediatric migraine remains underrecognized and frequently mischaracterized as an extension of adult disease, rather than a distinct clinical entity shaped by the dynamic processes of brain development. Recognition of pediatric migraine as a neurodevelopmentally modulated disorder is essential to advancing diagnosis, research, and treatment strategies[2].

Epidemiological burden and clinical impact

Migraine is among the most prevalent neurological disorders in childhood and adolescence, demonstrating a clear age- and sex-dependent pattern. Prevalence is approximately 2%-3% in early childhood, increases to 8%-10% during the school-age years, and reaches 15%-20% by late adolescence. Before puberty, migraine affects boys and girls at similar rates; however, following pubertal onset, prevalence rises disproportionately among females, resulting in a female-to-male ratio of approximately (2-3):1. This divergence closely parallels hormonal maturation and underscores the influence of sex-specific neurobiological and neuroendocrine factors on migraine susceptibility[3].

Beyond its increasing prevalence, pediatric migraine imposes a substantial and sustained functional burden. It is a leading cause of school absenteeism and presenteeism and is associated with impaired academic performance, reduced attention and executive functioning, and diminished participation in social and extracurricular activities. Population-based studies consistently show that children with migraine miss significantly more school days and report lower health-related quality-of-life scores compared with their peers[4].

The impact of pediatric migraine extends beyond the affected child to the family unit. Children and adolescents with migraine have higher rates of psychiatric comorbidities, including anxiety, depression, and sleep disturbances, reflecting a bidirectional relationship between migraine and mental health. Recurrent attacks disrupt family routines, contribute to caregiver stress, and generate a measurable economic burden through increased healthcare utilization and lost work productivity. Collectively, these effects position pediatric migraine as a chronic, disabling condition and a significant public health concern, rather than a benign or self-limited childhood disorder[2].

The historical evidence gap in pediatric migraine

For decades, the management of pediatric migraine relied heavily on extrapolation from adult clinical trials, a “trickle-down” paradigm that failed to account for developmental differences in neurobiology, pharmacokinetics, and treatment response. This approach resulted in widespread off-label use of medications with limited pediatric-specific efficacy and safety data. The limitations of this model were brought into sharp focus by the landmark Childhood and Adolescent Migraine Prevention (CHAMP) trial, which demonstrated an unexpectedly high placebo response and no significant superiority of amitriptyline or topiramate over placebo in children and adolescents[5]. These findings challenged long-standing assumptions regarding preventive pharmacotherapy and underscored a fundamental principle: Children with migraine are not simply “small adults” but represent a biologically and therapeutically distinct population.

A paradigm shift: From mechanisms to targeted therapeutics

The field of pediatric migraine is now undergoing a transformative shift driven by advances in neurobiology and translational science. Improved understanding of the trigeminovascular system, cortical excitability, and neuropeptide signaling, particularly involving calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP), has redefined migraine as a disorder of network dysfunction rather than isolated vascular pathology[6]. These insights have catalyzed the development of mechanism-based therapies, including small-molecule CGRP antagonists (gepants), serotonin 5-HT_1F receptor agonists (ditans), and monoclonal antibodies targeting CGRP or its receptor. Although much of the evidence originates from adult studies, pediatric and adolescent trials are rapidly expanding, signaling the emergence of a new era in age-appropriate, targeted migraine care[7].

Objective and scope of this review

This review aims to provide a comprehensive synthesis of pediatric migraine, integrating developmental neurobiology with contemporary clinical practice. Specifically, we examine the unique pathophysiological mechanisms underlying migraine in the developing brain and critically evaluate the evolving landscape of modern therapeutics, including pharmacologic, behavioral, and device-based interventions. By bridging foundational mechanisms with emerging clinical evidence, this article seeks to offer a pragmatic framework for personalized, evidence-based management of pediatric migraine, one that aligns therapeutic decisions with the biological and psychosocial realities of childhood and adolescence.

Methodology and literature search

Although this is a narrative review, a structured search was conducted to ensure comprehensive coverage. Databases including PubMed, EMBASE, and the Cochrane Library were searched for English-language articles published from January 2000 to January 2025. The keyword framework included: (pediatric OR adolescent) AND migraine AND (CGRP OR gepant OR neuromodulation OR pathophysiology OR episodic syndromes).

Inclusion priorities: Clinical practice guidelines (e.g., American Academy of Neurology/American Headache Society), randomized controlled trials (RCTs), systematic reviews, and meta-analyses. Exclusion Criteria: Studies focused solely on adult populations without pediatric stratification, isolated case reports, and non-peer-reviewed abstracts. The evidence cut-off date was January 15, 2026.

PATHOPHYSIOLOGY OF PEDIATRIC MIGRAINE: DEVELOPMENTAL MECHANISMS

The pathophysiology of pediatric migraine cannot be regarded as a mere developmental variant of adult disease. Rather, it reflects a dynamic interaction between genetically determined neural excitability and the ongoing maturation of central pain-processing networks. The pediatric migraine brain is characterized by heightened cortical and subcortical responsiveness, impaired inhibitory control, and a reduced threshold for sensory activation. These features are most prominent early in life, when neurodevelopmental plasticity is maximal, and are strongly shaped by genetic architecture[8].

Genetic susceptibility and channelopathies

High heritability and familial aggregation: Migraine is among the most highly heritable neurological disorders, with genetic factors accounting for up to 50%-70% of disease susceptibility. In pediatric migraine, the genetic contribution is often more pronounced than in adult-onset disease, as early manifestation frequently reflects a higher inherited biological burden. Familial aggregation is a consistent clinical feature; children with one affected parent carry an estimated 40%-50% lifetime risk of migraine, which increases to approximately 70%-75% when both parents are affected[9].

Importantly, what is inherited is not merely the propensity for headache, but a broader neurobiological phenotype characterized by heightened sensory sensitivity, vestibular instability, and altered autonomic regulation. In childhood, this inherited vulnerability often manifests initially as episodic syndromes associated with migraine, such as abdominal migraine, cyclic vomiting syndrome (CVS), or benign paroxysmal vertigo, frequently preceding the development of typical migraine headache by several years. These observations underscore the concept of migraine as a developmental disorder of neural excitability, with age-dependent phenotypic expression[10].

Monogenic migraine disorders, the channelopathy paradigm: The most compelling mechanistic evidence for migraines as a biological disorder derives from familial hemiplegic migraine (FHM), a rare autosomal dominant condition that serves as a monogenic model for migraine pathophysiology. FHM exemplifies how discrete disruptions in ion channel and transporter function can precipitate the migraine phenotype. Three primary genetic subtypes have been identified: FHM type 1 (CACNA1A), FHM type 2 (ATP1A2), and FHM type 3 (SCN1A)[11].

Mutations in CACNA1A (FHM type 1), encoding the α₁A subunit of the P/Q-type voltage-gated calcium channel, result in a gain-of-function effect. This leads to excessive presynaptic calcium influx and increased release of excitatory neurotransmitters, particularly glutamate, promoting cortical hyperexcitability and facilitating cortical spreading depression (CSD)[12]. Mutations in ATP1A2 (FHM type 2), encoding the α₂ subunit of the Na⁺/K⁺-ATPase pump primarily expressed in astrocytes, impair potassium and glutamate clearance from the synaptic cleft. This disruption destabilizes ionic homeostasis, lowers the threshold for neuronal depolarization, and creates a permissive environment for CSD propagation[13]. Mutations in SCN1A (FHM type 3), which encodes the α₁ subunit of the voltage-gated sodium channel Nav1.1, alter channel inactivation kinetics, leading to enhanced neuronal firing and interneuronal network instability[14].

Although monogenic migraine disorders are rare, they illuminate a unifying principle: Migraine, particularly in childhood, is fundamentally a disorder of ion channel and transporter dysfunction. In more common, non-hemiplegic migraine, subtler genetic variants affecting ion channels, including potassium channels such as TRESK (KCNK18), likely contribute to individual differences in cortical excitability and migraine susceptibility[15].

Polygenic risk and gene-environment interactions: For most pediatric patients, migraine arises from a complex polygenic architecture rather than single-gene mutations. Large-scale genome-wide association studies have identified more than 120 susceptibility loci, implicating genes involved in synaptic transmission, vascular regulation, neuronal development, and inflammatory signaling. Rather than determining disease in isolation, these variants collectively establish a state of neurobiological vulnerability[16].

In childhood and adolescence, this polygenic predisposition interacts dynamically with developmental and environmental factors (Figure 1). Puberty represents a critical inflection point, as hormonal changes, particularly rising estrogen levels, modulate gene expression and excitatory-inhibitory balance within the trigeminovascular system, contributing to the marked postpubertal increase in migraine prevalence among females[17]. Additionally, epigenetic mechanisms provide a biological interface between genes and environment; early-life stress, sleep disruption, nutritional deficiencies, and psychosocial adversity can induce lasting modifications in gene expression without altering the DNA sequence itself[18].

Figure 1 Genetic susceptibility and developmental modulation in pediatric migraine. Pediatric migraine arises from a spectrum of genetic mechanisms that interact dynamically with brain development. A: Rare monogenic forms, such as familial hemiplegic migraine, demonstrate how ion channel and transporter dysfunction (CACNA1A, ATP1A2, SCN1A) lead to neuronal hyperexcitability and a reduced threshold for cortical spreading depression; B: In most children, migraine reflects a polygenic architecture, with multiple common variants collectively influencing synaptic transmission, neurovascular signaling, and cortical excitability; C: Developmental and environmental modifiers, including pubertal hormonal changes, epigenetic regulation, sleep disruption, and psychosocial stress, interact with genetic vulnerability to trigger clinical migraine expression across childhood and adolescence.

This convergence of inherited susceptibility and environmental modulation explains the delayed or abrupt onset of migraine in many children. A genetically predisposed brain may remain clinically silent until a specific developmental transition or external stressor surpasses the individual’s excitability threshold, triggering the emergence of migraine as a recurrent clinical disorder[16].

Trigeminovascular system and neuropeptides

The headache phase of a migraine attack is mediated by activation of the trigeminovascular system, which represents the final common pathway for pain generation in both pediatric and adult migraine. In children, however, this system operates within an immature, highly plastic nervous system, conferring heightened sensitivity to sensory and neurovascular stimuli. The trigeminovascular system comprises a tightly integrated neurovascular unit, including primary afferent neurons of the trigeminal ganglion, meningeal and intracranial blood vessels, and central projections to the trigeminocervical complex (TCC) within the brainstem (Figure 2)[19].

Figure 2 Trigeminovascular activation, neuropeptide signaling, and evolution of pediatric migraine headache. Pediatric migraine headache arises from activation of the trigeminovascular system, the final common pathway for pain generation. Nociceptive A-δ and C-fibers from the trigeminal ganglion innervating the meninges and intracranial blood vessels are activated by genetic, developmental, and environmental triggers. This activation leads to the release of key neuropeptides, primarily calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide. Peripherally, these neuropeptides induce meningeal vasodilation and neurogenic inflammation, resulting in peripheral sensitization. Centrally, sustained signaling within the trigeminocervical complex enhances nociceptive transmission to thalamic and cortical pain networks, promoting central sensitization. The progressive amplification of trigeminovascular signaling culminates in the clinical migraine phenotype, characterized by throbbing headache, cutaneous allodynia, and prominent autonomic symptoms. Developmental factors unique to childhood and adolescence increase neuropeptide sensitivity, facilitating the transition from neurobiological activation to overt clinical headache. TCC: Trigeminocervical complex.

Activation and sensitization of trigeminovascular afferents: Migraine pain originates from the activation of nociceptive A-δ and C-fibers innervating the dura mater and large cerebral vessels. In pediatric migraine, activation of these afferents readily induces peripheral sensitization, characterized by reduced nociceptive thresholds and exaggerated responsiveness to physiological mechanical stimuli, such as arterial pulsation. Clinically, this mechanism underlies the characteristic throbbing quality of migraine pain[20].

As nociceptive input propagates centrally from the trigeminal ganglion to second-order neurons within the TCC, sustained activation leads to central sensitization, marked by amplified neuronal firing, expanded receptive fields, and impaired inhibitory modulation. This neuroplastic shift provides a mechanistic explanation for cutaneous allodynia, a feature increasingly recognized in adolescents with migraine and associated with more frequent attacks, longer disease duration, and reduced responsiveness to delayed acute therapy. The prominence of central sensitization in pediatric migraine underscores the importance of early and mechanism-based intervention (Figure 2)[21].

Neuropeptide signaling in the trigeminovascular system: Communication within the trigeminovascular network is mediated by vasoactive and neuromodulatory peptides released from activated trigeminal afferents. Among these, CGRP and PACAP have emerged as central effectors of migraine pathophysiology[22].

CGRP: CGRP is widely regarded as the principal molecular driver of the migraine attack. Peripherally, its release from trigeminal nerve endings produces potent and sustained vasodilation of meningeal arteries and initiates neurogenic inflammation through mast cell activation and plasma protein extravasation. Centrally, CGRP enhances synaptic transmission within the TCC and facilitates ascending nociceptive signaling to thalamic and cortical pain networks[23].

Importantly, accumulating evidence supports a pivotal role for CGRP in pediatric migraine. Clinical studies and meta-analyses have demonstrated significantly elevated serum CGRP levels in children and adolescents with migraine during both ictal and interictal phases, suggesting persistent trigeminovascular activation even between attacks. This sustained elevation positions CGRP not only as a pathogenic mediator but also as a potential biomarker of disease activity in younger populations, providing a strong biological rationale for CGRP-targeted therapies in pediatric care[24].

PACAP-38: PACAP-38, often described as a functional “counterpart” to CGRP, has gained increasing attention as an independent mediator of migraine. PACAP induces prolonged vasodilation of intracranial vessels and exerts powerful effects on parasympathetic outflow, linking trigeminal activation to autonomic symptoms. In pediatric migraine, PACAP signaling may contribute to prominent autonomic features, including facial pallor, periorbital darkening, lacrimation, and nasal congestion[25].

PACAP exerts its effects primarily through the PAC1 receptor, which modulates neuronal excitability within trigeminal pathways independently of CGRP signaling. This distinction has important therapeutic implications, as it may explain why some patients exhibit incomplete responses to CGRP-targeted treatments and highlights PAC1 as a potential future pharmacologic target[26].

Developmental signatures of neuropeptide signaling: Neuropeptide signaling within the trigeminovascular system is developmentally regulated and differs quantitatively and qualitatively from the adult state. Preclinical and translational studies suggest that the density of CGRP-containing fibers innervating the intracranial vasculature is relatively higher during early life and declines with maturation. This developmental profile likely contributes to a high-sensitivity neuropeptide milieu, rendering children more susceptible to exaggerated responses following relatively minor triggers[27].

Puberty represents a critical biological inflection point. Rising levels of estrogen and progesterone modulate both CGRP receptor expression and PACAP release, altering trigeminovascular excitability and contributing to the marked increase in migraine prevalence and severity observed during adolescence, particularly among females. These developmental and hormonal influences reinforce the concept of pediatric migraine as a disorder of evolving neurobiological networks rather than a static disease entity[28].

CSD

While activation of the trigeminovascular system accounts for migraine pain, CSD represents the key electrophysiological substrate underlying migraine aura and likely serves as a critical, often “silent”, initiator of downstream pain pathways. In children and adolescents, CSD unfolds within a distinctive neurodevelopmental environment characterized by heightened cortical plasticity and an evolving balance between excitatory and inhibitory neurotransmission[29].

Mechanistic basis of migraine aura: CSD is a slowly propagating wave of near-complete neuronal and glial depolarization that travels across the cerebral cortex at approximately 2-5 mm/minute. This event consists of two sequential phases that closely mirror the clinical features of migraine aura. The depolarization phase is the initial phase, marked by a massive efflux of potassium ions and by an influx of sodium and calcium into neurons and glial cells. These ionic shifts correspond to the positive neurological symptoms of aura, such as scintillating scotomas, visual distortions, paresthesia, or tingling sensations. The depolarization wave is followed by the depression phase, a prolonged period of neuronal hypoactivity or electrical silence, reflecting cortical suppression. Clinically, this phase correlates with negative aura symptoms, including visual field deficits, numbness, or transient focal neurological impairment[30,31].

Importantly, CSD is not merely an electrical phenomenon but also a potent metabolic and inflammatory stressor. As the wave propagates, it promotes the extracellular release of excitatory neurotransmitters and danger-associated molecules, including glutamate and ATP. These mediators diffuse toward the meninges, where they activate perivascular trigeminal afferents, thereby establishing CSD as a crucial mechanistic bridge between cortical dysfunction and trigeminovascular nociception[32].

Pediatric considerations, increased cortical excitability: The pediatric brain exhibits intrinsic hyperexcitability compared with the adult brain. During childhood and early adolescence, ongoing synaptic proliferation and pruning result in a transient predominance of excitatory synapses and increased expression of N-methyl-D-aspartate receptors. This neurodevelopmental state significantly lowers the threshold for initiating a CSD event[33].

Clinically, this heightened susceptibility manifests in several characteristic pediatric migraine phenotypes. Aura without headache is particularly common in younger children, where CSD may occur without sufficient activation of downstream inflammatory or trigeminovascular pathways to produce overt headache. On the other hand, relatively mild stimuli, such as flickering lights, brief fasting, minor dehydration, or sleep disruption, may be sufficient to provoke CSD in children, whereas the same stimuli would remain subthreshold in adults[34].

Immature inhibitory networks and failure of CSD suppression: The propagation and containment of CSD critically depend on effective inhibitory neurotransmission, predominantly mediated by gamma-aminobutyric acid (GABA). In the developing brain, inhibitory circuits are not yet fully mature, contributing further to CSD vulnerability[35]. Early in neurodevelopment, GABA may paradoxically exert excitatory effects due to differential expression of chloride transporters (predominantly NKCC1 over KCC2), resulting in less effective inhibitory control. Because cortical inhibitory interneurons function as the brain’s intrinsic “braking system”, their immaturity allows initiated CSD waves to propagate more readily or recur more frequently in pediatric patients[36].

This developmental imbalance, characterized by excessive glutamatergic excitation coupled with insufficient GABAergic inhibition, creates a neurobiological “perfect storm” that may predispose children to recurrent migraine attacks and eventual chronification. Recognizing this mismatch is essential for understanding age-specific therapeutic responses and explains why neuromodulatory strategies or membrane-stabilizing agents (such as topiramate) may demonstrate differential efficacy in pediatric vs adult migraine populations[37].

The developing brain and pain processing

The pediatric brain is not a static substrate upon which migraine mechanisms are simply superimposed; rather, it is an evolving neurobiological system in which ongoing maturation of structure, connectivity, and modulation profoundly shapes pain perception. The distinctive clinical phenotype of pediatric migraine, shorter duration, bilateral distribution, and prominent autonomic features, is a direct consequence of developmental neurobiology, particularly the refinement of neural networks and sensory filtering mechanisms[38].

Neurodevelopmental remodeling, synaptic pruning and myelination: Two fundamental neurodevelopmental processes, synaptic pruning and myelination, play central roles in determining how migraine-related nociceptive signals are generated, propagated, and interpreted during childhood[39].

Synaptic pruning and network efficiency. In early childhood, the cerebral cortex is characterized by an overabundance of synaptic connections, resulting in a state of relative hyperconnectivity. While this architecture confers heightened sensitivity and plasticity, it lacks the efficiency and specificity seen in the mature brain[40]. During development, activity-dependent synaptic pruning selectively eliminates redundant or inefficient connections, leading to more streamlined and specialized neural networks[41]. Prior to this refinement, migraine-related activation is more diffuse, which likely explains why children often describe a global sense of illness, fatigue, or malaise rather than a sharply localized headache. Pain, in this context, is experienced as a widespread cerebral event rather than a focal phenomenon[42].

Myelination and functional connectivity. Myelination of axonal pathways, which enhances conduction velocity and temporal precision, continues from infancy through adolescence and into early adulthood. In children, incomplete myelination of long-range association fibers and interhemispheric pathways, particularly within the corpus callosum, limits efficient lateralization and gating of nociceptive input. As a result, pain signals are more broadly distributed across hemispheres, favoring bilateral or holocranial headache presentations typical of pediatric migraine[43].

Maturation of brainstem and thalamocortical pain networks: Pain perception is not solely a function of peripheral input but is critically shaped by central modulation. Two interconnected systems, the thalamocortical sensory relay and the descending inhibitory pain pathways, undergo prolonged maturation during childhood[44]. The thalamus serves as the principal relay and filter for sensory information destined for the cortex. In the developing brain, thalamocortical gating mechanisms are comparatively permissive, allowing excessive sensory input to reach higher cortical centers. This “leaky filter” state provides a mechanistic explanation for the profound photophobia, phonophobia, and sensory overload observed in pediatric migraine, even when headache intensity is modest. Sensory hypersensitivity is thus not ancillary but a core feature of migraine expression in children[45].

Descending pain modulatory pathways originating in the periaqueductal gray, rostral ventromedial medulla, and related brainstem nuclei constitute the brain’s endogenous analgesic system. These circuits, which exert top-down inhibition on trigeminovascular nociceptive transmission, mature relatively late in development. Consequently, the pediatric brain exhibits a functional imbalance characterized by robust excitatory drive with insufficient inhibitory control. Once activated, trigeminovascular signaling is more difficult to suppress, predisposing children to rapid symptom escalation despite relatively modest triggers[46].

Developmental explanations for key pediatric migraine phenotypes: The interaction between immature connectivity, heightened excitability, and limited inhibitory capacity produces several hallmark clinical features that distinguish pediatric migraine from its adult counterpart (Figure 3). While adult migraine attacks are defined by a minimum duration of four hours, pediatric attacks are frequently resolved within one to two hours. This abbreviated course may reflect the higher cerebral metabolic rate of the developing brain and a more rapid turnover of neuropeptides such as CGRP[47]. In children, the neurovascular cascade is intense but transient, the migraine “storm” develops quickly and often resolves before sustained central sensitization can be established[2].

Figure 3 Neurodevelopmental maturation shapes the pediatric migraine phenotype. This schematic summarizes how ongoing brain maturation influences the distinctive clinical expression of migraine in children and adolescents. During early childhood, incomplete synaptic pruning and limited myelination result in diffuse neural connectivity and inefficient sensory gating, predisposing to heightened cortical excitability and widespread activation in response to migraine triggers. Immature thalamocortical filtering and underdeveloped descending inhibitory pain pathways further amplify sensory input and autonomic responses. Collectively, these developmental features manifest clinically as shorter migraine attacks, predominantly bilateral or holocranial head pain, and prominent gastrointestinal and autonomic symptoms. As neurodevelopment progresses through late childhood and adolescence, refinement of synaptic networks, improved myelination, and maturation of inhibitory control promote more localized pain processing and contribute to the gradual transition toward the adult migraine phenotype.

Unlike the predominantly unilateral presentation of adult migraine, pediatric migraine is typically bilateral, most often involving frontal or temporal regions. This pattern directly mirrors immature hemispheric specialization and incomplete lateralization of pain-processing networks. As cortical and subcortical circuits mature through adolescence, migraine pain increasingly adopts the classic unilateral distribution seen in adults[48]. Children with migraines frequently exhibit marked autonomic symptoms, including nausea, vomiting, facial pallor, and periorbital darkening. The pediatric brain is particularly sensitive to activation of the brain-gut axis, with strong coupling between the trigeminal nuclei and autonomic centers in the brainstem[49]. Anatomical and functional proximity between the trigeminal sensory complex and the dorsal motor nucleus of the vagus nerve facilitates early parasympathetic activation during migraine attacks. This explains why gastrointestinal symptoms and entities such as abdominal migraine may dominate the clinical picture, at times overshadowing head pain itself[1].

Mechanistic differences between pediatric-and adult-onset migraine: The distinction between pediatric-onset and adult-onset migraine is not merely a matter of duration or pain location; it is rooted in the neurodevelopmental stage of the brain. While the “final common pathway” (the trigeminovascular system) is shared, the mechanisms that initiate and modulate these attacks differ significantly. There are many key mechanistic differences[50].

The “genetic load” and threshold mechanism. Pediatric migraine is often characterized by a higher genetic load. In children, the disease frequently presents earlier because the biological threshold for triggering an attack is lower, often due to a denser aggregation of risk alleles. While adult migraine is often influenced by a lifetime of environmental “wear and tear” (allostatic load), pediatric migraine is driven by primary channelopathies and intrinsic neuronal hyperexcitability. This is why children are more prone to “migraine equivalents” (like abdominal migraine) where the brainstem effectors are mature enough to trigger symptoms, but the cortical pain pathways are not yet fully sensitized to the adult “hemicrania” pattern[48,51].

Neurochemical imbalance: The GABA/glutamate paradox. Recent magnetic resonance spectroscopy studies have revealed a striking “reverse profile” between children and adults in the levels of primary excitatory and inhibitory neurotransmitters. Adults typically show increased glutamate in the visual cortex and thalamus, indicating a state of chronic excitation. Surprisingly, symptomatic children (specifically those with aura) often show lower glutamate levels in the visual cortex compared to healthy peers[52]. This suggests that the pediatric migrainous brain may be struggling with metabolic inefficiency or a failure of glutamate cycling rather than just “simple” over-excitation. Furthermore, the pediatric brain’s GABAergic (inhibitory) system is still maturing, meaning the “brakes” of the brain are less effective at quenching a wave of CSD[53].

Neuropeptide signaling: CGRP vs PACAP. While CGRP is the “gold standard” target in adult migraine, the neuropeptide landscape in children shows more nuance. Research suggests that PACAP and vasoactive intestinal peptide may play a more dominant role in the pediatric population[54]. This explains why children have a higher prevalence of cranial autonomic symptoms (redness of the eyes, flushing of the ears, periorbital shadows) and gastrointestinal symptoms than adults. The pediatric trigeminal system is more tightly “wired” to the parasympathetic outflow than its adult counterpart[55].

Structural maturity and pain lateralization. The most obvious clinical difference, bilateral vs unilateral pain, is driven by the state of myelination and interhemispheric connectivity. In children, the corpus callosum and the pathways for “descending pain modulation” (the brain’s internal pharmacy) are not yet fully mature. Without a mature inhibitory system to lateralize or “gate” the pain, the activation of the trigeminovascular system in children tends to be holocranial (bilateral). As the brain matures and lateralization of function increases during late adolescence, the classic adult pattern of unilateral (hemicranial) pain emerges[56,57].

The pubertal biological switch. Puberty acts as a massive “mechanistic pivot”. In pre-pubertal children, the prevalence of migraine is slightly higher in boys. The surge of estrogen in females doesn’t just change the frequency; it changes the mechanism. Estrogen modulates CGRP receptor sensitivity and increases mu-opioid receptor density in the brainstem. This “hormonal priming” is what transforms pediatric migraine into the cyclic, often more severe, adult female phenotype[58]. Table 1 shows a mechanistic comparison between pediatric and adult-onset migraine.

Table 1 Mechanistic comparison between pediatric and adult-onset migraine.

Feature	Pediatric onset	Adult onset
Primary driver	Genetic load/channelopathy	Environment/hormonal/allostatic load
Glutamate profile	Often decreased in the visual cortex	Typically increased
Dominant neuropeptides	PACAP, VIP, and CGRP	Primarily CGRP
Pain pattern	Bilateral (immature modulation)	Unilateral (mature lateralization)
Autonomic involvement	High (GI and facial symptoms)	Moderate (standard cranial symptoms)

PACAP: Pituitary adenylate cyclase-activating polypeptide; VIP: Vasoactive intestinal polypeptide; CGRP: Calcitonin gene-related peptide; GI: Gastrointestinal.

CLINICAL PHENOTYPES AND DIAGNOSTIC CONSIDERATIONS

Recurrent headaches in childhood most often represent a primary headache disorder, with migraine and tension-type headache accounting for most cases. Pediatric migraine typically presents as episodic head pain that is frequently bilateral and accompanied by nausea, vomiting, and heightened sensitivity to light or sound, and it may include age-specific variants or prominent autonomic features[59]. In contrast, tension-type headache is generally milder, more diffuse, and lacks significant associated symptoms. Although secondary headache disorders are relatively uncommon, their recognition is critical because they may indicate serious intracranial, infectious, vascular, or systemic disease[60]. Accurate differentiation relies primarily on a detailed clinical history, identification of red-flag features, and a focused neurological examination, rather than routine neuroimaging (Table 2).

Table 2 Key clinical features differentiating pediatric headache types.

Feature	Migraine	Tension-type headache	Secondary headache
Typical onset	Episodic, recurrent	Gradual, often stress-related	Acute or progressive
Pain quality	Pulsating/throbbing	Pressing/tight	Variable
Pain location	Bilateral (frontotemporal) in children	Bilateral, diffuse	Often focal or occipital
Intensity	Moderate to severe	Mild to moderate	Variable, often severe
Activity worsens pain	Yes	No	Variable
Nausea/vomiting	Common	Absent	Possible
Photo-/phonophobia	Common	Absent or mild	Variable
Autonomic features	Common in children	Rare	Possible
Neurological exam	Normal	Normal	Often abnormal
Response to sleep	Marked improvement	Minimal effect	Poor or absent

The diagnosis of migraine in children and adolescents requires an approach that departs from adult-centric headache paradigms and accounts for developmental context. Pediatric migraine exhibits age-dependent features that differ in both symptom expression and disease trajectory, reflecting ongoing brain maturation. Younger children, in particular, may be unable to clearly describe internal sensory experiences such as photophobia or phonophobia, necessitating reliance on behavioral cues, caregiver observations, and longitudinal symptom patterns[61]. Consequently, effective diagnostic assessment integrates clinical observation with developmental awareness, ensuring that migraine is accurately identified despite variability in communication skills and evolving clinical phenotypes.

Diagnostic criteria: Pediatric vs adult migraine

The International Classification of Headache Disorders, third edition (ICHD-3) provides specific adaptations for individuals under 18 years of age, reflecting the neurodevelopmental principles outlined in the preceding section. These modifications acknowledge that migraine phenomenology evolves with brain maturation and that rigid application of adult criteria risks systematic underdiagnosis in children[62].

Key pediatric adaptations in ICHD-3: The most clinically relevant distinctions between pediatric and adult migraine criteria involve attack duration, pain location, and symptom reporting. In adults, migraine attacks must last at least four hours if they are untreated or unsuccessfully treated. In contrast, pediatric criteria permit a duration of 2-72 hours, recognizing the shorter, more rapidly resolving attacks typical of childhood migraine[63]. Although attacks in very young children may be even briefer, the two-hour minimum remains the formal diagnostic threshold. Regarding the location of the headache, while adult migraine is characteristically unilateral, pediatric migraine is most often bilateral, particularly in the frontotemporal regions[50]. Unilateral (hemicranial) pain typically emerges only in late adolescence, coinciding with the maturation of hemispheric specialization and pain lateralization. Because children may struggle to verbalize abstract sensory phenomena such as photophobia or phonophobia, the ICHD-3 permits inferring these symptoms from observable behavior. Examples include seeking a dark or quiet environment, covering the eyes or ears, irritability with noise or light, or a strong desire to sleep during an attack[64].

Common diagnostic pitfalls: Despite clear criteria, pediatric migraine is frequently misdiagnosed due to several recurring misconceptions. For example, cranial autonomic symptoms, such as nasal congestion, rhinorrhea, or lacrimation, are common in migraine due to trigeminovascular and parasympathetic activation; these features often lead to erroneous diagnoses of recurrent sinusitis, particularly in the absence of objective evidence of infection[65]. In addition, the classic description of “throbbing” or “pulsating” pain may be absent or difficult for younger children to articulate. Use of age-appropriate visual aids or analogies can facilitate more accurate symptom characterization. A distinctive hallmark of pediatric migraine is rapid symptom resolution with sleep. A history of severe distress followed by deep sleep and complete recovery upon awakening is highly suggestive of migraine and should prompt focused diagnostic consideration. Figure 4 shows a flowchart for diagnosing childhood migraine[42].

Figure 4 Pediatric migraine diagnostic flow chart. This flowchart provides a structured clinical pathway for the evaluation and diagnosis of pediatric migraine, emphasizing the distinction between primary headache disorders, secondary pathologies, and age-specific migraine equivalents. ICHD-3: International Classification of Headache Disorders, third edition.

Episodic syndromes associated with migraine

One of the most distinctive features of pediatric migraine biology is the presence of episodic syndromes associated with migraine, often referred to as migraine equivalents. In these conditions, the neurobiological machinery of migraine, particularly brainstem, autonomic, and gut-brain axis dysfunction, is active, while head pain is absent or secondary[66].

Abdominal migraine: It is characterized by recurrent, paroxysmal episodes of intense midline or periumbilical abdominal pain lasting 1-72 hours. Abdominal migraine is frequently accompanied by pallor, anorexia, nausea, and vomiting. Complete resolution of symptoms between attacks is essential for diagnosis[67].

CVS: CVS manifests with stereotyped episodes of severe nausea and vomiting occurring at predictable intervals, often leading to dehydration and hospital admission. Substantial clinical, genetic, and metabolic overlap exists between CVS and migraine, including shared mitochondrial vulnerability and strong familial migraine histories[68].

Benign paroxysmal vertigo and benign paroxysmal torticollis: Benign paroxysmal torticollis typically manifests in infancy as recurrent episodes of head tilt lasting minutes to days, often accompanied by pallor or irritability. Benign paroxysmal vertigo occurs in toddlers and young children, presenting as brief episodes of disequilibrium, vertigo, nystagmus, or vomiting, with complete interictal recovery[69].

The migraine march: The “migraine march” describes the characteristic developmental evolution of migraine expression across childhood. Rather than presenting initially as a typical headache disorder, migraine in the developing brain often manifests through age-specific episodic syndromes, in which non-headache symptoms predominate and change as neural networks mature[70]. These conditions are not distinct or isolated diagnoses; instead, they represent developmentally timed expressions of a shared underlying migrainous biology. Many children follow a predictable trajectory, from benign paroxysmal torticollis in infancy, to cyclic vomiting syndrome, benign paroxysmal vertigo, or abdominal migraine in early childhood, and ultimately to migraine with or without aura during adolescence. Recognition of this continuum is essential for early diagnosis, appropriate anticipatory guidance, and the avoidance of unnecessary investigations (Figure 5)[71].

Figure 5 The migraine march through childhood. This figure illustrates the developmental trajectory of migraine-related disorders across childhood, often referred to as the migraine march. Many children exhibit age-dependent manifestations, beginning in infancy with benign paroxysmal torticollis (A), progressing during early childhood to cyclic vomiting syndrome and/or abdominal migraine (B), and ultimately evolving into migraine with or without aura during adolescence (C). The arrows indicate the temporal and developmental progression of these episodic.

Red flags and exclusion of secondary headache disorders

Although migraine is the most frequent cause of recurrent headaches in children, clinicians must remain vigilant for secondary etiologies, including intracranial mass lesions, infections, vascular abnormalities, and idiopathic intracranial hypertension[72].

The SNOOP10 framework: The SNOOP10 mnemonic provides a structured approach to identifying warning signs that warrant further evaluation[73]. In pediatric practice, particular attention should be paid to: S, systemic features: Fever, unexplained weight loss, or systemic illness; N, neurological abnormalities: Focal deficits, papilledema, ataxia, or abnormal eye movements; O, onset characteristics: Sudden “thunderclap” headache or strictly occipital pain; O, age considerations: New-onset headache in children under five years of age; P, pattern change or progression: Increasing frequency or severity, headaches triggered by valsalva maneuvers, or nocturnal awakening due to headache.

Indications for neuroimaging: Routine neuroimaging is not recommended for children with recurrent headaches that are stereotypical, meet migraine criteria, and are accompanied by a normal neurological examination. However, magnetic resonance imaging, preferably avoiding ionizing radiation, should be pursued in the presence of abnormal neurological examination (e.g., focal deficits or papilledema), headaches consistently precipitated by coughing, straining, or exertion, new-onset severe headaches occur in children younger than five years, and/or a significant or unexplained change in headache phenotype[74].

MODERN THERAPEUTICS I: ACUTE MANAGEMENT

The overarching objective of acute migraine management in children and adolescents is the rapid and sustained resolution of headache pain and associated symptoms, thereby restoring normal function and minimizing disruption to school attendance, play, and psychosocial development. Contemporary pediatric migraine care has moved decisively away from a passive “wait-and-see” paradigm toward an early, mechanism-informed, and evidence-based intervention strategy. This shift reflects growing recognition that delayed treatment not only reduces therapeutic efficacy but also increases the risk of attack prolongation and progression[75].

Principles of acute treatment in children

In pediatric migraine, the effectiveness of acute therapy is determined less by the specific pharmacologic agent selected and more by the timing, context, and consistency of treatment administration. Optimal outcomes require a strategic approach that integrates neurobiological principles with practical, child-centered care (Figure 6)[75].

Figure 6 Algorithm for early and stratified acute management of pediatric migraine attacks. This flow chart depicts a mechanism-informed strategy for aborting acute migraine attacks in children and adolescents, prioritizing rapid return to function. Early intervention (“window of opportunity”): Emphasizes the critical importance of administering treatment within the first 20-60 minutes of attack onset. Treating during this peripheral activation phase prevents the development of central sensitization (cutaneous allodynia), significantly increasing the success rate of abortive therapy. Stratified care approach (phase A vs phase B): Treatment selection is based on attack severity at onset or history of previous treatment response. Phase A (first line): Utilizes weight-based simple analgesics (ibuprofen, acetaminophen, naproxen) for mild-to-moderate attacks. Naproxen is highlighted for longer-duration attacks due to its half-life. Phase B (specific therapy): Utilizes triptans (age-appropriate formulations like oral disintegrating tablet or nasal spray) for moderate-to-severe attacks or as “rescue” if phase A fails within 60 minutes. Emerging therapies (gepants, ditans) are considered for patients contraindicated to or intolerant of triptans. Monitoring and medication overuse headache: The red pathway highlights the risk of medication overuse headache. Clinicians must track usage limits (≤ 14 days/month for simple analgesics, ≤ 9 days/month for triptans). Exceeding these thresholds indicates failure of the acute strategy and necessitates immediate escalation to preventive management. MOH: Medication overuse headache; NSAID: Non-steroidal anti-inflammatory drug.

Importance of early intervention: The “window of opportunity”: Neurobiological studies suggest that the pediatric migrainous brain progresses rapidly from peripheral trigeminovascular activation to central sensitization, often within 20-60 minutes of attack onset. Once central sensitization develops, clinically manifesting as cutaneous allodynia and heightened sensory sensitivity, the response to acute therapies diminishes substantially[76]. Intervening during the early, predominantly peripheral phase of the migraine cascade interrupts nociceptive signaling before central amplification occurs, markedly increasing the likelihood of achieving pain freedom and sustained relief[77]. Children and caregivers should be explicitly instructed to administer acute treatment at the earliest recognizable signs of a migraine attack, rather than delaying therapy until pain severity escalates. In practice, this often requires a pre-prepared “rescue kit”, including medications and supportive measures, within the school setting[78].

Avoiding medication overuse headache: While early treatment is vital, frequent use of acute medications can paradoxically increase headache frequency, a phenomenon known as medication overuse headache (or “transformed migraine”). In the pediatric population, it is strictly advised to limit the use of simple analgesics [non-steroidal anti-inflammatory drugs (NSAIDs)/acetaminophen] to no more than 14 days per month, and specific treatments (triptans) to no more than 9 days per month[79]. Overuse leads to a downregulation of serotonin receptors and a further lowering of the pain threshold, making the brain more susceptible to future attacks. Clinicians must balance the imperative for early treatment with vigilant monitoring of medication frequency, particularly in children with high attack burden[80].

Child- and family-centered acute treatment plans: Acute migraine management in children should be implemented as a coordinated, child- and family-centered strategy rather than a purely pharmacologic intervention. Optimal care combines early use of appropriate medications with simple supportive measures, including hydration, brief rest or sleep, and environmental modification to a cool, dark, quiet setting[81]. Key components include an individualized “headache toolkit”, explicit instructions for treatment escalation, and clear, realistic therapeutic goals. Providing a written headache action plan for school personnel is particularly beneficial, as it enables timely intervention, supervised rest, and continuity of care, which often prevents unnecessary school dismissal and fosters the child’s independence in symptom management[82]. Families should be advised that treatment success is best defined by sustained relief of pain and associated symptoms within two hours, rather than immediate resolution, as appropriate expectation-setting improves adherence and long-term outcomes. Access to acute timely treatment particularly within the school environment, also represents an important equity issue[83]. Delayed intervention is more common among socioeconomically disadvantaged children and is associated with increased school absenteeism, greater reliance on emergency care, and a higher risk of migraine chronification. Ensuring reliable access to rescue medications and school-based support is therefore both a clinical necessity and a core element of comprehensive pediatric migraine care[84].

First-line therapies: Simple analgesics

For mild-to-moderate migraine attacks, or as the initial step within a stratified or stepped-care model, simple analgesics remain the cornerstone of acute pediatric migraine management. Despite their apparent simplicity, their effectiveness in children is highly contingent upon timely administration and appropriate weight-based dosing[85]. Inadequate dosing or delayed use is a leading cause of perceived therapeutic failure in routine clinical practice. The efficacy of NSAIDs in pediatric migraine is supported by a robust body of evidence. Among available agents, ibuprofen is the most extensively studied acute therapy in children and adolescents[86]. Multiple RCTs have demonstrated significantly higher rates of pain freedom at 2 hours compared with placebo, establishing ibuprofen as a first-line standard of care. Ibuprofen exerts its therapeutic effect by non-selectively inhibiting cyclooxygenase (COX-1 and COX-2), reducing the synthesis of pro-inflammatory prostaglandins that sensitize trigeminovascular nociceptors. When administered early and at appropriate doses, ibuprofen provides reliable analgesia with a favorable safety profile[87].

Naproxen sodium has a slower onset of action compared with ibuprofen; however, its longer elimination half-life confers an important clinical advantage in children prone to headache recurrence, defined as the return of migraine pain within 24 hours after initial resolution. This pharmacokinetic property makes naproxen particularly useful in prolonged or relapsing attacks[88]. Although generally less effective than NSAIDs for moderate-to-severe migraine attacks, acetaminophen remains a critical option for children with contraindications to NSAIDs, including gastritis, renal impairment, bleeding disorders, or NSAID intolerance. When used early and at adequate doses, acetaminophen can be effective for mild attacks and is often better tolerated in younger children. Subtherapeutic dosing is a frequent and preventable contributor to treatment failure. To achieve plasma concentration sufficient to interrupt the migraine cascade, weight-based dosing must be strictly applied (Table 3)[89].

Table 3 Standardized acute pharmacotherapy: Weight-based dosing.

Agent	Pediatric dose (mg/kg)	Max single dose	Monthly limit	Monitoring/safety
Ibuprofen	10 mg/kg	800 mg	< 14 days/month	Take with food; avoid in active gastritis or renal impairment
Acetaminophen	15 mg/kg	1000 mg	< 14 days/month	Hepatic safety; check for “hidden” sources in OTC products
Naproxen	5-10 mg/kg	500 mg	< 14 days/month	Preferred for long-duration attacks due to 12 hours half-life
Sumatriptan	Nasal spray: 5-20 mg	20 mg	< 9 days/month	Monitor for “triptan sensations” (chest/neck tightness)

OTC: Over-the-counter.

While first-line analgesics are generally well tolerated, expert pediatric migraine management requires careful attention to safety nuances. Repeated NSAID exposure may cause dyspepsia or gastritis. In children with gastrointestinal sensitivity, administration with food or milk is strongly recommended. Doses exceeding recommended weight-based limits do not enhance analgesic efficacy and substantially increase the risk of renal impairment and gastrointestinal bleeding[90]. Acetaminophen safety depends on strict adherence to a maximum cumulative daily dose of 75 mg/kg/day, as exceeding this threshold may overwhelm hepatic metabolic pathways and result in liver injury. The use of simple analgesics for more than 14 days per month is the primary driver of medication overuse headache in adolescents and must be actively monitored[91].

Triptans in pediatric migraine

When first-line analgesics fail to provide relief within 30 to 60 minutes, or for attacks that are moderate-to-severe from onset, triptans are the treatment of choice. Triptans are selective 5-HT_1B/1D receptor agonists that act by constricting painfully dilated cranial blood vessels, inhibiting the release of pro-inflammatory neuropeptides (like CGRP), and modulating pain transmission in the brainstem[78].

United States Food and Drug Administration/European Medicines Agency-approved agents by age group: While triptans have been the mainstay of adult migraine treatment for adults for decades, only a select few have received formal regulatory approval for the pediatric population (Table 4). The “gap” between adult and pediatric approval is largely due to the high placebo response rate often seen in pediatric clinical trials[92].

Table 4 The different Food and Drug Administration-approved triptans used to treat childhood migraine.

Medication	Age group (FDA)	Age group (EMA)	Key features
Rizatriptan (Maxalt)	6-17 years	≥ 18 years1	Currently the only triptan FDA-approved for children as young as 6. Available as an ODT
Zolmitriptan nasal spray	12-17 years	12-17 years	First nasal-delivered triptan approved for adolescents. Offers rapid absorption and high efficacy for associated symptoms
Almotriptan	12-17 years	12-17 years	Often cited for having a superior tolerability profile with fewer “triptan sensations” (chest/neck tightness)
Sumatriptan/naproxen	12-17 years		A fixed-dose combination (Treximet) that targets both the neural (triptan) and inflammatory (NSAID) pathways

¹While European regulators (European Medicines Agency) often defer to national approvals for younger ages, sumatriptan nasal spray is the most widely approved pediatric triptan across Europe for those > 12 years.

EMA: European Medicines Agency; FDA: Food and Drug Administration; ODT: Orally disintegrating tablet; NSAID: Non-steroidal anti-inflammatory drugs.

The choice of formulation is often more critical than the specific triptan molecule, particularly in a population where nausea and vomiting are prominent. Rizatriptan and zolmitriptan are available in oral disintegrating tablets (ODTs) formats. These are ideal for children who have difficulty swallowing pills or who are at school without easy access to water[93]. However, it is a common misconception that ODTs are absorbed in the mouth; they are still swallowed with saliva and absorbed in the gastrointestinal tract, meaning they are still subject to migraine-induced gastroparesis (delayed stomach emptying). Zolmitriptan and sumatriptan nasal sprays bypass the digestive system. Nasal sprays provide a faster onset of action (often within 15 minutes) and remain effective even if the child is actively vomiting. Some children find the bitter “aftertaste” of nasal sprays (which drip down the throat) aversive, which can impact compliance. Proper administration, tilting the head slightly forward rather than backward, can mitigate this[94]. Oral sumatriptan alone has historically performed poorly in pediatric RCTs (no better than placebo). If a child fails oral sumatriptan, it should not be considered a “class failure”; they may still respond robustly to a nasal formulation or to rizatriptan. Triptans are contraindicated in children with rare forms of migraine (hemiplegic or basilar type) or known cardiovascular disease, though the absolute risk of vascular events in healthy children is exceedingly low. Failure of one triptan formulation should not be interpreted as class failure[95,96].

Triptans in pediatric migraine

When first-line analgesics fail to provide relief within 30 to 60 minutes, or for attacks that are moderate-to-severe from onset, triptans are the treatment of choice. Triptans are selective 5-HT_1B/1D receptor agonists that act by constricting painfully dilated cranial blood vessels, inhibiting the release of pro-inflammatory neuropeptides (such as CGRP), and modulating pain transmission in the brainstem[78].

Pediatric evidence: Triptans have been extensively studied in the pediatric population, though regulatory approval varies. Rizatriptan is United States Food and Drug Administration-approved for children aged 6 years to 17 years. For adolescents (12 years to 17 years), approved agents include almotriptan, zolmitriptan nasal spray, and the sumatriptan/naproxen combination tablet[92]. Clinical trials for these agents involved several thousand pediatric participants (e.g., rizatriptan trials included over 1000 subjects). The primary endpoint in these studies is typically pain freedom at 2 hours. While triptans are effective, pediatric RCTs often struggle to demonstrate superiority over placebo because of an exceptionally high placebo response rate (sometimes exceeding 50%), which is significantly higher than that observed in adult trials[92].

Adult extrapolation and limitations: The use of triptans in children was initially extrapolated from robust adult data showing high efficacy and safety. However, this extrapolation had significant limitations. The pediatric migrainous brain has a different neurovascular maturity level, leading to shorter attack durations. Adult data failed to predict the high placebo response in children, which led to many early pediatric triptan trials (especially for oral sumatriptan) failing to meet primary endpoints despite the drug being biologically active[92,95]. Safety data on cardiovascular events were also extrapolated from adults; however, the absolute risk in healthy children is significantly lower because they lack atherosclerotic disease.

Clinical positioning, formulations, and contraindications: Triptans are indicated for pediatric patients who do not respond to weight-based NSAIDs or who present with moderate-to-severe intensity attacks from onset. The choice of delivery is critical. ODTs, such as rizatriptan or zolmitriptan, are useful for school-based care where water may not be accessible[93]. However, as ODTs are swallowed with saliva and absorbed in the gastrointestinal tract, they remain susceptible to migraine-induced gastroparesis. Nasal sprays (zolmitriptan and sumatriptan) bypass the digestive system, providing a faster onset (within 15 minutes) and continued efficacy during active vomiting[94].

Triptans remain contraindicated in children with rare migraine subtypes (e.g., hemiplegic or basilar-type migraine) and those with known cardiovascular or cerebrovascular disease. Clinicians should not interpret the failure of one triptan or formulation as a class failure. Patients who fail to respond to oral sumatriptan may still respond robustly to nasal zolmitriptan or oral rizatriptan[95,96].

Emerging acute therapies

The most significant shift in the modern migraine landscape is the development of “designer” molecules that bypass the cardiovascular risks associated with triptans. For the pediatric population, particularly adolescents with complex medical histories or those who do not tolerate the “triptan sensations” (chest and neck tightness), these emerging therapies represent the next frontier of care[97].

Gepants, small-molecule CGRP receptor antagonists: Gepants, such as ubrogepant and rimegepant, are small-molecule CGRP receptor antagonists. Unlike triptans, they do not cause vasoconstriction, making them a safer alternative for patients with vascular concerns. Gepants work by competitive antagonism at the CGRP receptor. By blocking CGRP from binding to its receptors on vessel walls and in the trigeminal system, they effectively “turn off” the neurogenic inflammation and vasodilation that drive migraine pain without affecting systemic blood pressure or vessel tone[7].

Ubrogepant is currently under investigation in phase 3 trials for children and adolescents (ages 6-17). Early data suggest a safety profile similar to that seen in adults, with nausea and somnolence being the most common, albeit infrequent, side effects. Rimegepant is unique for its dual-use potential (both acute and preventive)[98]. Pediatric trials are actively assessing its efficacy in an ODT format, which is well-suited to the pediatric “on-the-go” lifestyle. The absence of vasoconstrictive effects makes gepants especially attractive for patients with contraindications to triptans or those experiencing frequent adverse effects. However, at present, these agents should be considered investigational in children outside clinical trials or specialist centers[99].

Ditans, selective 5-HT_1F agonists: The only current member of this class is lasmiditan. While it targets the serotonin system, like triptans, it is highly selective and does not share their side-effect profile. Unlike triptans, which target 5-HT_1B/1D receptors found on blood vessels, lasmiditan has a high affinity for the 5-HT_1F receptor located primarily on the trigeminal nerve endings and within central pain-processing centers (the thalamus and brainstem)[100]. It inhibits the release of neuropeptides and stops the transmission of pain signals centrally without causing any vasoconstriction. Because lasmiditan crosses the blood-brain barrier so effectively, the primary side effects are central nervous system-related: Dizziness, somnolence, and paresthesia. In the adolescent population, the “driving restriction” (a mandated 8-hour wait after dosing in adults) is a significant clinical consideration[101]. Ongoing pediatric studies are focusing on whether lower weight-based doses can maintain efficacy while minimizing these dizzying effects, which could interfere with a student’s school day. Table 5 provides a comparative overview of emerging and traditional therapies for the acute treatment of migraine attacks in children. While advances in acute therapeutics have dramatically improved symptom control, long-term outcomes in pediatric migraine often depend on effective preventive strategies, particularly for children with frequent, disabling, or chronic attacks[102].

Table 5 Comparative overview of traditional vs emerging acute therapies.

Feature	Triptans	Gepants (emerging)	Ditans (emerging)
Primary target	5-HT1B/1D	CGRP receptor	5-HT1F receptor
Vasoconstriction	Yes	No	No
Primary SE	Chest/neck tightness	Nausea, dry mouth	Dizziness, somnolence
Pediatric status	FDA/EMA approved (selected)	Phase 3 trials (6-17 years)	Ongoing trials (6-17 years)
Clinical role	Standard 2nd-line	Refractory/vascular contraindication	Refractory/vascular contraindication

SE: Side effects; EMA: European Medicines Agency; FDA: Food and Drug Administration; CGRP: Calcitonin gene-related peptide.

Emerging acute therapies

The most significant shift in the modern migraine landscape is the development of “designer” molecules that bypass the cardiovascular risks associated with triptans. For the pediatric population, particularly adolescents with complex medical histories or those who do not tolerate “triptan sensations” (chest and neck tightness), these emerging therapies represent the next frontier of care[97].

Gepants, small-molecule CGRP receptor antagonists: Gepants, such as ubrogepant and rimegepant, are small-molecule CGRP receptor antagonists. Unlike triptans, they do not cause vasoconstriction; instead, they target neurogenic inflammation and vasodilation that drive migraine pain without affecting systemic blood pressure[7]. Ubrogepant is currently under investigation in phase 3 trials (e.g., the ACHIEVE and PRODIGY programs) for children and adolescents aged 6-17 years. Early safety data from these cohorts suggest a profile similar to adults, with nausea and somnolence as the most common, albeit infrequent, side effects. Rimegepant is also being evaluated in pediatric trials (ages 6-17) using an ODT format. The primary endpoints in these trials are pain freedom at 2 hours and freedom from the most bothersome symptom[98,99].

The efficacy of gepants in the pediatric population is currently extrapolated from robust adult phase 3 trials showing significant superiority over placebo for acute relief. However, a major limitation of this extrapolation is the lack of long-term data regarding the impact of blocking CGRP, a potent vasodilator and neuropeptide, on the developing cardiovascular and endocrine systems in growing children. At present, gepants are considered investigational and should be reserved for use in specialist centers or clinical trials[99]. They are specifically positioned for adolescents who have failed ≥ 2 triptans or have absolute contraindications to vasoconstrictive agents (e.g., Raynaud’s phenomenon or history of cardiovascular events).

Ditans, selective 5-HT_1F agonists: The only current member of this class is lasmiditan. While it targets the serotonin system like triptans, it is highly selective for the 5-HT_1F receptor[100]. Ongoing pediatric studies (e.g., CENTURION-Pediatric) are investigating lasmiditan in children and adolescents aged 6-17 years. The primary efficacy endpoint is pain freedom at 2 hours. Clinical data in children are still maturing, with a focus on determining weight-based dosing that avoids excessive sedation.

Adult studies show that lasmiditan is highly effective because it crosses the blood-brain barrier to stop pain signals centrally without causing vasoconstriction. A critical limitation in extrapolating this to the pediatric population is the high incidence of central nervous system side effects. In adults, there is a mandated 8-hour driving restriction after dosing due to dizziness and somnolence[101]. This poses a significant clinical concern for students, as the drug may impair school-day alertness and safety.

Lasmiditan is positioned as an alternative for patients who fail triptans or have vascular contraindications. However, its use is currently limited by concerns about its side-effect profile. It should be avoided in children where immediate return to high-level cognitive activity (e.g., a school day or athletic performance) is required within 8 hours of the attack[102]. Table 5 provides a comparative overview of emerging and traditional therapies for the acute treatment of migraine attacks in children. While advances in acute therapeutics have dramatically improved symptom control, long-term outcomes in pediatric migraine often depend on effective preventive strategies, particularly for children with frequent, disabling, or chronic attacks[102].

MODERN THERAPEUTICS II: PREVENTIVE STRATEGIES

Lifestyle and behavioral interventions

Preventive management in pediatric migraine begins not with pharmacology, but with targeted lifestyle and behavioral modification. This approach reflects both the developmental plasticity of the pediatric brain and the strong influence of environmental, behavioral, and psychosocial factors on migraine expression. Importantly, these interventions are not “adjunctive” or optional; they form the foundation upon which all effective preventive strategies are built (Figure 7)[92].

Figure 7 A bio-behavioral and stepped preventive strategy for pediatric chronic or frequent migraine. This flow chart outlines a developmentally appropriate, stepped-care model for reducing attack frequency and disability in children with frequent episodic or chronic migraine. The bio-behavioral foundation represents the non-negotiable first step for all patients, regardless of disease severity. It addresses modifiable triggers through sleep hygiene, hydration, nutrition, and stress management (including cognitive behavioral therapy/biofeedback), acknowledging the high susceptibility of the pediatric brain to environmental stabilization. Decision threshold (“significant impairment”): Pharmacologic or nutraceutical escalation is only indicated if the bio-behavioral foundation fails to reduce functional impairment (e.g., continued school absenteeism). Stepped pharmacotherapy, phase A (nutraceuticals): The preferred first line of medical prevention due to a favorable safety profile. Options include magnesium, riboflavin, and coenzyme Q10. High placebo response rates in this category are noted as a therapeutic leverage point. Phase B (traditional pharmacotherapy): Reflects the post-CHAMP trial paradigm where traditional agents (topiramate, amitriptyline, propranolol) are chosen specifically to address comorbidities (e.g., anxiety, insomnia, obesity) rather than as reflexive first-line agents, given their equivalence to placebo in recent major trials. Phase C (targeted prevention): Reserves novel anti-calcitonin gene-related peptide monoclonal antibodies for adolescents meeting definitions of refractory chronic migraine (failure of traditional preventives). Assessment loop: Emphasizes that prevention is dynamic. Adequate therapeutic trials require 8-12 weeks before re-evaluation, at which point therapy is continued, adjusted, or tapered based on response. CoQ10: Coenzyme Q10; CBT: Cognitive behavioral therapy; CGRP: Calcitonin gene-related peptide.

The biopsychosocial framework: Pediatric migraine is best understood, and most effectively treated, through a biopsychosocial lens, recognizing the dynamic interaction between biological vulnerability, psychological stressors, and environmental triggers. Lifestyle regularity serves as a stabilizing force for an intrinsically hyperexcitable brain[103].

Sleep regularity: Sleep disturbance is one of the most potent and under-recognized migraine triggers in children. Irregular sleep-wake cycles, insufficient sleep duration, and “weekend sleep debt” destabilize hypothalamic and brainstem networks involved in pain modulation. Preventive counseling should emphasize consistent bedtimes and wake times (including on weekends), age-appropriate sleep duration, and limiting evening screen exposure and caffeine intake. Improvement in sleep regularity alone can lead to substantial reductions in attack frequency in a subset of patients[104].

Hydration and nutrition: Children are particularly vulnerable to dehydration-related migraine due to higher metabolic demands and less reliable thirst signaling. Skipped meals, especially breakfast, can precipitate attacks via hypoglycemia-induced cortical excitability. Preventive strategies include structured hydration goals (often quantified in school-aged children), regular meal patterns with attention to breakfast, and avoidance of prolonged fasting rather than rigid elimination diets. The focus should remain on consistency rather than restrictive dietary rules, which may increase anxiety and reduce adherence[105].

Stress management and emotional regulation: Psychosocial stressors, academic pressure, social dynamics, and family stress, are powerful migraine amplifiers in children. Unlike adults, children often somatize emotional distress, with migraine serving as a primary stress signal. Preventive care must therefore include identification of stress triggers, normalization of stress-migraine links for families, and development of adaptive coping strategies. Failure to address stress often leads to escalation of pharmacologic therapy without durable benefit[106].

Cognitive-behavioral therapy and biofeedback: Among non-pharmacological interventions, cognitive-behavioral therapy (CBT) has the strongest evidence base for pediatric migraine prevention. CBT targets maladaptive thought patterns and behavioral responses that perpetuate migraine disability, such as catastrophizing, fear of pain, and activity avoidance. RCTs have consistently shown that CBT, either alone or combined with medication, reduces headache frequency, pain-related disability, and school absenteeism. Notably, CBT outcomes often outperform pharmacologic monotherapy in adolescents with chronic migraines[107].

Biofeedback and relaxation training: Biofeedback helps children gain voluntary control over physiological processes linked to migraine, including muscle tension, skin temperature, and autonomic tone. By enhancing parasympathetic activity and reducing sympathetic overdrive, biofeedback directly counteracts the autonomic dysregulation central to pediatric migraine pathophysiology[108].

Clinical integration: Lifestyle and behavioral interventions should be introduced early, framed positively, and revisited at every follow-up visit. When presented as skill-building rather than “restrictions”, adherence improves substantially. Importantly, these strategies reduce reliance on acute medications, decrease the risk of medication-overuse headache, and enhance the effectiveness of pharmacologic preventives when needed. In pediatric migraine, successful prevention is rarely achieved by medication alone. Instead, it emerges from restoring rhythm, predictability, and resilience to a developing nervous system that is exquisitely sensitive to disruption[109,110].

Traditional pharmacologic prevention

For decades, preventive pharmacotherapy in pediatric migraine mirrored adult practice, with widespread off-label use of antiepileptics, antidepressants, and antihypertensives. However, accumulating pediatric-specific evidence, most notably from the CHAMP trial, has fundamentally reshaped how these agents are viewed. Traditional preventives remain important tools, but their use now requires greater selectivity, shared decision-making, and integration with non-pharmacologic strategies[111].

Commonly used preventive agents: Topiramate. Topiramate is the only traditional preventive agent with formal United States Food and Drug Administration approval for migraine prevention in adolescents (ages 12-17). Its mechanism is pleiotropic, targeting several pathways implicated in migraine pathophysiology. It inhibits voltage-gated sodium and calcium channels, enhances GABAergic inhibitory signaling, suppresses glutamatergic transmission via AMPA/kainate receptors, and modulates cortical excitability and CSD thresholds[112]. Clinically, topiramate can be effective in reducing attack frequency, particularly in adolescents with frequent or chronic migraine. However, tolerability is a major limitation in the pediatric population. Cognitive side effects (“word-finding difficulty”, slowed processing), paresthesia, appetite suppression, and weight loss are common reasons for discontinuation. These effects are particularly consequential in school-aged children and mandate slow titration and careful monitoring[113].

Amitriptyline. Amitriptyline has historically been one of the most frequently prescribed pediatric migraine preventives. Its presumed benefits derive from its modulation of serotonergic and noradrenergic pain pathways, enhancement of descending inhibitory control, and sedative effects that may improve comorbid sleep disturbance[114]. Despite extensive clinical use, robust pediatric efficacy data are limited. Amitriptyline may be most appropriate for children with prominent comorbidities such as insomnia, anxiety, or functional abdominal pain. Adverse effects, including sedation, anticholinergic symptoms, weight gain, and potential cardiac conduction effects, necessitate baseline electrocardiogram assessment and cautious dosing[115].

Propranolol. Propranolol, a non-selective beta-adrenergic blocker, has long been used in pediatric migraine prevention based on adult efficacy and early pediatric trials. Its proposed mechanisms include dampening adrenergic hyperarousal, modulating central noradrenergic pain circuits, and stabilizing vascular and autonomic tone. In practice, propranolol may be beneficial in adolescents with comorbid performance anxiety or tremor[116]. However, its use is limited by pediatric contraindications, including asthma, diabetes, and bradycardia. Fatigue and exercise intolerance may be particularly problematic in physically active children and athletes[117]. Table 6 compares common traditional pharmacologic agents used to prevent pediatric migraine.

Table 6 Traditional pharmacologic preventives for pediatric migraine: Rapid comparison.

Agent	Topiramate	Amitriptyline	Propranolol
Mechanism of action	Enhances GABAergic inhibition; inhibits glutamatergic transmission; ion channel modulation	Serotonergic and noradrenergic reuptake inhibition	Non-selective β-adrenergic blockade
Strength of evidence (pediatrics)	Moderate (FDA-approved ≥ 12 years; CHAMP showed no superiority to placebo)	Moderate (FDA-approved ≥ 12 years; CHAMP showed no superiority to placebo)	Low-moderate (small trials, mixed results)
Typical starting pediatric dose1	Start 0.5-1 mg/kg/day	Start 0.25-0.5 mg/kg at bedtime	0.5 mg/kg (divided)
Titration (weekly)	Increase by 0.5 mg/kg to 1-2 mg/kg/day	Increase by 0.25 mg/kg	Increase by 0.5 mg/kg
Max dose	Max 100 mg/day	Max 1 mg/kg/day (usually ≤ 50 mg)	2-4 mg/kg (max 160 mg)
Key limitations/monitoring	Cognitive slowing, paresthesia, weight loss	Sedation, weight gain, anticholinergic effects	Contraindicated in children with asthma or diabetes
Practical considerations	Avoid children with learning difficulties; monitor weight, cognition, and mood	Baseline ECG recommended; high placebo response	May benefit comorbid anxiety; monitor heart rate blood pressure and exercise tolerance
Contraindication	Nephrolithiasis, glaucoma	Cardiac conduction defects	Asthma, diabetes, depression

¹Doses reflect commonly used ranges from pediatric headache guidelines and expert consensus; individualization and slow titration are recommended.

GABA: Gamma-aminobutyric acid; FDA: Food and Drug Administration; ECG: Electrocardiogram.

The CHAMP paradigm and decision thresholds for prevention: The CHAMP trial represents a watershed moment in pediatric headache medicine. This large, multicenter, RCT compared amitriptyline (1.0 mg/kg/day), topiramate (2.0 mg/kg/day), and placebo in children and adolescents aged 8 to 17 years with episodic migraine (defined as 4-14 headache days per month). The primary endpoint was a ≥ 50% reduction in headache days over 24 weeks[118].

Clinical significance and the placebo response: The study showed that both active medications failed to demonstrate superiority over placebo in reducing headache frequency or disability. Notably, the trial revealed a strikingly high placebo response, with approximately 61% of the placebo group achieving the primary endpoint, compared to 52% and 55% in the amitriptyline and topiramate groups, respectively. Furthermore, adverse events, including paresthesia, fatigue, and mood changes, were significantly more common in the active treatment arms[118].

By challenging the long-standing assumption that pharmacologic prophylaxis should be the default strategy, the CHAMP results underscore that the developing brain is uniquely responsive to expectancy, reassurance, and structured care. This suggests that the bio-behavioral foundation (sleep regularity, hydration, and CBT) is often as potent as pharmacotherapy in this population[119,120].

Thresholds for initiating pharmacologic prevention: Following the CHAMP trial, clinical guidelines have shifted toward a more selective use of preventive medications. The decision to escalate from lifestyle modification to pharmacotherapy should be informed by objective measures of disability, such as the Pediatric Migraine Disability Assessment (PedMIDAS).

Initiation of preventive therapy is now generally reserved for children who meet the following thresholds. Attack frequency: ≥ 4 migraine days per month. Disability scores: A PedMIDAS score > 30, indicating moderate-to-severe disability. Functional impact: ≥ 1-2 missed school days per month or significant “presenteeism” (inability to function while at school) despite optimized acute rescue therapy. Failure of lifestyle optimization: Lack of improvement after 8-12 weeks of strict adherence to bio-behavioral “headache hygiene”.

Practice pearls, comorbidity-oriented selection: When the above thresholds are met, and pharmacologic prevention is indicated, the choice of agent should be tailored to the patient’s comorbid profile to maximize the “benefit-to-side-effect” ratio. Topiramate is preferred for adolescents with comorbid obesity (due to weight loss potential) or epilepsy[112,113]. Amitriptyline is best suited for children with comorbid insomnia, anxiety, or functional gastrointestinal disorders (e.g., cyclic vomiting)[114,115]. Propranolol is ideal for patients with comorbid essential tremor or performance anxiety, provided there is no history of asthma or depression[116,117]. Nutraceuticals [magnesium/coenzyme Q10 (CoQ10)] are often used as the first step in prevention for families hesitant to start “heavy” prescription medications or for those with milder disability[118,120].

Reconsidering routine pharmacologic prophylaxis: In the post-CHAMP era, routine pharmacologic prophylaxis for pediatric migraine should no longer be the reflexive default; instead, preventive medications should be reserved for children experiencing significant functional impairment despite optimized lifestyle and behavioral interventions, ensuring therapy is tailored to specific comorbidities such as sleep disturbance, anxiety, obesity, or asthma[121]. This evolved strategy requires that pharmacotherapy be initiated only after explicit discussions regarding realistic goals, time-limited trials, and predefined stopping rules, shifting the role of traditional agents from first-line therapy to carefully selected, context-specific tools within a broader, developmentally informed framework. Furthermore, the high placebo response observed in the CHAMP trial should be recognized not as a methodological nuisance but as a testament to the therapeutic power of validation, education, and structured follow-up, emphasizing that the pediatric brain is uniquely responsive to a multidisciplinary approach that prioritizes expectancy and reassurance alongside medical intervention[122,123].

Nutraceuticals and complementary approaches

Nutraceuticals occupy a unique and increasingly important position in pediatric migraine prevention. Positioned at the intersection of lifestyle medicine and pharmacotherapy, these agents are particularly attractive in children and adolescents due to their favorable safety profiles, ease of use, and high family acceptance (Table 7). In the post-CHAMP era, where the emphasis has shifted toward minimizing medication burden, nutraceuticals often serve as first-line or adjunctive preventive options, especially mild-to-moderate disease. However, formal clinical guidelines for the use of nutraceuticals in pediatric migraine prevention are lacking, and the available studies provide limited and inconsistent evidence of efficacy[124].

Table 7 Comparison of common pediatric migraine nutraceuticals.

Nutraceutical	Biological rationale	Clinical evidence	Typical pediatric dosing	Key adverse effects
Magnesium	Modulates NMDA receptors; inhibits cortical spreading depression; reduces CGRP release	Modest but supportive; specifically effective for migraines with aura	5-10 mg/kg/day (elemental), often divided	Dose-dependent diarrhea; abdominal cramping
Riboflavin (vitamin B2)	Addresses mitochondrial dysfunction by enhancing electron transport chain efficiency	Some randomized trials show reduced frequency; high placebo response noted in children	200-400 mg/day (often used in doses higher than RDA)	Benign bright yellow discoloration of urine (chromaturia)
Coenzyme Q10	Acts as an antioxidant and essential cofactor in mitochondrial energy production	Shown to reduce headache frequency and severity in children with low levels	1-3 mg/kg/day (typically 100 mg daily)	Rare gastrointestinal upset or insomnia; generally extremely well-tolerated

NMDA: N-methyl-D-aspartate; CGRP: Calcitonin gene-related peptide; RDA: Recommended dietary allowance.

Magnesium: Magnesium provides a compelling biological rationale for pediatric migraine prevention, given its central role in modulating neuronal excitability and synaptic transmission. Its efficacy is linked to its ability to counteract N-methyl-D-aspartate receptor-mediated glutamatergic excitation, enhance CSD inhibition, and reduce CGRP release from trigeminal neurons. This mechanistic link is further supported by observations that children with migraines frequently exhibit lower intracellular magnesium levels[125].

From a clinical perspective, while the pediatric evidence base for magnesium remains modest, results from randomized and open-label studies are generally supportive, indicating notable reductions in both attack frequency and severity, especially among children who experience migraine with aura. Although magnesium oxide is the most frequently studied formulation, clinicians must account for variations in bioavailability across preparations[126]. Typical pediatric dosing ranges from 5-10 mg/kg/day of elemental magnesium, administered in divided doses. While magnesium maintains an excellent safety margin in children with normal renal function, its primary adverse effect, dose-dependent diarrhea, frequently limits tolerability, necessitating a gradual titration strategy to achieve therapeutic levels[127].

Riboflavin (vitamin B₂): Riboflavin is a critical cofactor in mitochondrial oxidative metabolism. Given the growing recognition of mitochondrial dysfunction in migraine pathophysiology, particularly in pediatric migraine equivalents such as cyclic vomiting syndrome, riboflavin has emerged as a biologically compelling preventive strategy. Evidence in children is mixed[128]. Small, randomized trials and observational studies suggest benefits in reducing migraine frequency, especially at higher doses and with prolonged use. However, some pediatric RCTs have failed to demonstrate superiority over placebo, likely reflecting high placebo responsiveness and heterogeneity in dosing[129]. Typical pediatric dosing ranges from 100-400 mg/day, with adolescents generally requiring higher doses to achieve efficacy. Riboflavin is extremely safe; the most notable side effect is harmless yellow-orange discoloration of urine, which should be proactively explained to families to improve adherence[130].

CoQ10: CoQ10 is an essential component of the mitochondrial electron transport chain and a potent antioxidant. Low serum CoQ10 levels have been documented in subsets of children with migraine, supporting its use as a targeted metabolic supplement. Observational studies and small interventional trials suggest that CoQ10 supplementation is associated with reductions in headache frequency and disability scores in pediatric migraineurs[131]. While high-quality randomized controlled data remain limited, the consistency of benefit across studies and its mechanistic plausibility have led to widespread clinical adoption. Dosing typically ranges from 1-3 mg/kg/day (often 100-300 mg/day in adolescents). CoQ10 is well tolerated, with rare reports of mild gastrointestinal discomfort. Its favorable safety profile makes it particularly appealing for long-term use in younger children. Table 7 compares common pediatric migraine nutraceuticals[132].

In contemporary pediatric migraine care, nutraceuticals have evolved from being viewed as “alternative” therapies to being recognized as biologically grounded interventions with growing empirical support. Compared to pharmacologic preventives, nutraceuticals such as magnesium, riboflavin, and CoQ10 are supported by lower-certainty evidence but offer superior tolerability and a highly favorable risk-benefit profile. Their clinical role is best conceptualized as a first-line preventive therapy for children with mild to moderate migraine, or as an adjunctive therapy used alongside behavioral interventions and pharmacologic agents. Furthermore, they serve as a pragmatic option for families seeking non-pharmacologic approaches, effectively bridging the gap between lifestyle modification and pharmacologic escalation within a developmentally sensitive, stepped preventive strategy[131,133].

The therapeutic value of these agents extends beyond their biological mechanisms; they likely leverage the same psychological factors, expectancy, engagement, and adherence, that contribute to the high placebo response observed in pediatric migraine trials. For clinical success, it is essential to provide clear counseling regarding precise dosing and realistic expected timelines, as these interventions typically require 8-12 weeks of consistent use before efficacy can be accurately assessed[134]. By setting these expectations and discussing potential side effects, clinicians can prevent premature discontinuation and ensure that nutraceuticals remain a safe, accessible, and well-accepted component of the patient's comprehensive care plan.

Targeted prevention: Anti-CGRP monoclonal antibodies

The advent of monoclonal antibodies targeting the CGRP pathway represents the most significant paradigm shift in migraine prevention in decades. These agents, designed to interrupt the final common molecular pathway of migraine, offer unprecedented specificity and durability of effect. In pediatric migraine, particularly among adolescents with frequent or refractory disease, anti-CGRP monoclonal antibodies have emerged as a highly promising, though still cautiously adopted, preventive strategy[135].

Mechanistic rationale: CGRP plays a central role in trigemino-vascular activation, neurogenic inflammation, and central sensitization. Unlike traditional preventives, which were repurposed from epilepsy, depression, or cardiovascular medicine, anti-CGRP monoclonal antibodies were developed explicitly for migraine biology. Their mechanisms include inhibition of CGRP-mediated vasodilation, suppression of neuropeptide-driven peripheral and central sensitization, and reduction of sustained trigeminal nociceptive signaling[136].

The fundamental distinction in this class lies in the target: Erenumab blocks the CGRP receptor itself, preventing the CGRP molecule from binding and initiating the pain cascade[137]. In contrast, fremanezumab, galcanezumab, and eptinezumab act as “sponges” that bind directly to the circulating CGRP ligand, neutralizing it before it can reach the receptor. While both pathways effectively inhibit trigeminovascular activation, the receptor blockade used by erenumab has been more frequently associated with constipation in both adult and pediatric retrospective studies, likely due to the presence of CGRP receptors in the enteric nervous system[138,139]. Table 8 shows the differences between these group members.

Table 8 Comparison of calcitonin gene-related peptide monoclonal antibodies in pediatric patients.

Feature	Erenumab (Aimovig)	Fremanezumab (Ajovy)	Galcanezumab (Emgality)	Eptinezumab (Vyepti)
Mechanism	Targets the CGRP receptor	Targets the CGRP ligand	Targets the CGRP ligand	Targets the CGRP ligand
Route	Subcutaneous injection	Subcutaneous injection	Subcutaneous injection	Intravenous infusion
Dosing frequency	Monthly	Monthly or quarterly	Monthly	Quarterly (every 12 weeks)
Pediatric evidence	Phase 3 trials (OASIS) recently completed/ongoing.	Strong evidence from phase 3 SPACE study; FDA filed for pediatric indication	Phase 3 trials ongoing; shown efficacy in small retrospective cohorts	Phase 3 trials (PROSPECT-1) ongoing; unique for its IV rapid onset
Key safety notes	Association with constipation (unique to receptor blockade)	Most common AE is injection-site erythema	Most common AE is injection-site reaction	Potential for infusion-related reactions; high safety rating in meta-analyses

CGRP: Calcitonin gene-related peptide; FDA: Food and Drug Administration; AEs: Adverse events.

Current evidence for the use of anti-CGRP monoclonal antibodies in adolescents is derived primarily from open-label extension studies, retrospective cohort analyses, and accumulating real-world clinical experience. Collectively, these data indicate that adolescents with high-frequency episodic or chronic migraine experience clinically meaningful reductions in monthly migraine days, significant improvements in headache-related disability, and favorable tolerability profiles that closely mirror those observed in adult populations[140]. Notably, treatment response appears most robust in adolescents with a well-defined migraine phenotype and documented failure of multiple conventional preventive therapies. In parallel, several randomized, placebo-controlled trials are currently underway in children and adolescents aged 6-17 years[141]. These studies incorporate pediatric-specific outcome measures, such as functional indices like school attendance and health-related quality of life, rather than relying solely on headache frequency. Although regulatory approval for adolescent use is anticipated, it remains contingent upon the availability of long-term safety and efficacy data[142].

The introduction of biologic therapies in children raises important ethical and developmental considerations that extend beyond short-term clinical benefit. CGRP is a pleiotropic neuropeptide with established roles in vascular development, endothelial function, bone metabolism, skeletal growth, gastrointestinal motility, and immune modulation. While no major developmental safety signals have been identified to date, the theoretical implications of sustained CGRP suppression during critical growth periods necessitate ongoing vigilance and long-term surveillance[143]. Furthermore, unlike adults, children and adolescents may experience spontaneous improvement or remission of migraine as neurodevelopment progresses. Consequently, preventive strategies should incorporate regular reassessment of therapeutic necessity every 6-12 months, consideration of trial discontinuation following sustained remission, and clear communication with families that anti-CGRP therapy is not inherently lifelong[144]. Issues of equity and access further complicate clinical implementation, as high cost, insurance authorization barriers, and off-label prescribing raise ethical concerns that must be transparently addressed within a shared decision-making framework.

In current pediatric practice, anti-CGRP monoclonal antibodies are best positioned as third-line or advanced preventive options for adolescents with chronic migraine or high-frequency episodic migraine who have failed or not tolerated at least two traditional preventive therapies and who continue to experience substantial functional impairment despite optimized lifestyle and behavioral interventions. Their use should occur within a structured clinical framework that includes comprehensive baseline assessment, standardized outcome monitoring, and long-term safety follow-up[145]. From a broader perspective, anti-CGRP monoclonal antibodies represent a major milestone in pediatric migraine prevention, introducing mechanism-based precision to a field long dominated by empiricism. However, their application in a developing population demands a higher evidentiary and ethical threshold than in adults[146]. As robust pediatric trial data continue to emerge, these agents are poised to redefine the upper tier of preventive therapy and move pediatric migraine management closer to truly personalized, biology-driven care. We should emphasize that anti-CGRP therapies should not replace lifestyle, behavioral, and sleep interventions but complement them[147].

NEUROMODULATION AND DEVICE-BASED THERAPIES

Rationale for neuromodulation in pediatric migraine

Neuromodulation has emerged as an increasingly attractive therapeutic strategy in pediatric migraine, driven by the need for effective, non-pharmacologic interventions with favorable safety profiles. In children and adolescents, where developmental considerations, medication tolerability, and long-term safety are paramount, device-based therapies offer a compelling alternative or adjunct to conventional pharmacologic approaches[148].

A defining advantage of neuromodulation lies in its mechanism-agnostic, drug-free nature. By delivering targeted electrical or magnetic stimulation to peripheral nerves or central pain networks, these devices modulate neuronal excitability and disrupt migraine-related signaling without altering systemic biochemical pathways[149]. This is particularly appealing in pediatrics, where families often express concern about the long-term medication exposure during critical periods of neurodevelopment, the cumulative adverse effects from preventive pharmacotherapy, and the polypharmacy in children with comorbid neurobehavioral or medical conditions[150]. Neuromodulation aligns well with a biopsychosocial model of care, reinforcing patient autonomy and active engagement in treatment. Many devices can be self-administered, empowering adolescents to manage attacks proactively and enhancing adherence through a sense of control rather than dependence on daily medication[151].

Unlike pharmacologic therapies, neuromodulation does not rely on hepatic metabolism, renal clearance, or cardiovascular modulation. As a result, systemic adverse effects are rare. Reported side effects are typically localized (e.g., mild paresthesia, skin irritation), transient, and reversible with device discontinuation[152]. This safety profile is particularly advantageous for children who have contraindications to triptans or preventive medications, experience intolerable side effects from standard therapies, or are at risk for medication-overuse headache. Importantly, neuromodulation does not carry the theoretical developmental concerns associated with long-term suppression of neuropeptides or neurotransmitter systems. While long-term pediatric data remain limited, current evidence suggests a high margin of safety when devices are used as intended[153].

Clinical implications

Given these attributes, neuromodulation is best conceptualized not as a replacement for pharmacotherapy but as an early adjunct in treatment-resistant cases, a bridge therapy while preventive medications are optimized, and a primary option for families seeking non-drug interventions. As pediatric-specific trials mature and device designs become more user-friendly, neuromodulation is poised to occupy a central role in personalized, stepwise migraine management for children and adolescents (Table 9 and Figure 8)[154].

Figure 8 Non-invasive neuromodulation devices used in the management of pediatric migraine. This schematic illustrates currently available non-pharmacological neuromodulation modalities for pediatric and adolescent migraine, highlighting their sites of application and therapeutic concepts. A: Remote electrical neuromodulation (Nerivio^®), a wearable upper-arm device that delivers conditioned pain modulation via peripheral nociceptive stimulation, remotely modulating central pain pathways; B: External trigeminal nerve stimulation (Cefaly^®), a forehead-mounted device that stimulates the supraorbital branches of the trigeminal nerve to reduce trigeminovascular excitability; C: Single-pulse transcranial magnetic stimulation (eNeura/SAVI Dual^™), a handheld device applied to the occipital cortex, delivering brief magnetic pulses that interrupt cortical spreading depression and modulate cortical excitability; D: Non-invasive vagus nerve stimulation (gammaCore^®), a cervical device that stimulates the vagus nerve to engage brainstem pain-inhibitory and autonomic regulatory circuits; E: External combined occipital and trigeminal neurostimulation, a head-mounted system targeting both occipital and trigeminal nerve territories, aiming to simultaneously modulate cortical and trigeminovascular networks involved in migraine pathophysiology. Together, these devices represent a growing class of mechanism-based, drug-free therapeutic options particularly suited for pediatric patients who have contraindications to pharmacotherapy, poor tolerability, or preference for non-medication approaches.

Table 9 Comparison of key pediatric neuromodulation devices used for migraine management.

Device/modality	Target/mechanism	Pediatric age approval	Acute use	Preventive use	Evidence and notes
Remote electrical neuromodulation (Nerivio®)	Upper-arm electrical stimulation enhancing conditioned pain modulation. This descending analgesic mechanism reduces pain in distant body regions (the head). It stimulates C and Aδ nerve fibers	FDA-cleared ≥ 12 years; expanding to 8 years in some jurisdictions	Yes	Yes	Open-label and real-world data show pain relief and functional improvement in adolescents; minimal AEs and high acceptability
External trigeminal nerve stimulation (Cefaly®)	Supraorbital trigeminal nerve stimulation. The device stimulates the supraorbital trigeminal nerve, the primary pathway for migraine pain, helping to modulate and desensitize it	Used off-label in pediatrics; FDA cleared for adults	Yes	Yes	Adult data supports efficacy/safety; device modulates trigeminal afferents with minimal side effects, and pediatric tolerability appears acceptable
Single-pulse transcranial magnetic stimulation (eNeura/SAVI Dual™)	Magnetic pulses modulating cortical excitability by creating a small electrical current in the cortex to “reset” overactive brain nerves associated with migraines, without causing pain	FDA-cleared ≥ 12 years (adolescents)	Yes	Yes	Open-label adolescent studies show feasibility and tolerability; larger RCTs needed for efficacy confirmation
Non-invasive vagus nerve stimulation (gammaCore®)	Cervical vagal nerve stimulation influencing brainstem pain pathways	FDA-cleared ≥ 12 years	Yes	Yes	Small pediatric studies suggest relief in adolescents; generally, well tolerated with mild neck discomfort
External combined occipital and trigeminal neurostimulation (Relivion®)	Dual occipital + trigeminal stimulation	Adult cleared; pediatric off label	Yes	Potential	Adult data supports acute migraine use, pediatric evidence currently limited

AEs: Adverse events; FDA: Food and Drug Administration; RCTs: Randomized controlled trials.

Neuromodulation devices provide a valuable non-systemic therapeutic alternative with a minimal side-effect profile, making them an increasingly attractive option for children and adolescents who either do not tolerate or fail to respond to traditional pharmacologic preventives. Among these technologies, remote electrical neuromodulation, single-pulse transcranial magnetic stimulation, and non-invasive vagus nerve stimulation have received formal United States Food and Drug Administration clearance for use in adolescents, typically defined as those aged twelve years and older[155]. While many of these devices are utilized off-label in younger children under specialist physician oversight, the current pediatric evidence base is strongest for remote electrical neuromodulation, supported by both open-label studies and real-world clinical cohorts[156].

Other modalities, such as external trigeminal nerve stimulation, single-pulse transcranial magnetic stimulation, and non-invasive vagus nerve stimulation, are supported by adolescent data and proven efficacy in adults, although large-scale RCTs in pediatric populations remain limited[157]. Across all these treatment modalities, reported adverse events in pediatric populations are generally mild and localized, such as transient tingling or skin discomfort, with no systemic side effects documented to date. This favorable safety profile positions neuromodulation as a vital component of a developmentally sensitive, multidisciplinary approach to pediatric migraine management[158].

Practical integration of neuromodulation in pediatrics

When integrating neuromodulation into a pediatric migraine care plan, several principles apply. Devices such as incorporating remote electrical neuromodulation and single-pulse transcranial magnetic stimulation are most effective when used early in the attack, ideally at the first sign of pain or associated symptoms[159]. Neuromodulation can be used alongside acute pharmacotherapy (e.g., NSAIDs, triptans) or, in select cases, as a primary acute strategy when medications are contraindicated or poorly tolerated. remote electrical neuromodulation, external trigeminal nerve stimulation, and single-pulse transcranial magnetic stimulation have demonstrated preventive benefits either through designated protocols or emerging evidence, supporting their role in chronic or high-frequency headache management[160]. The absence of systemic adverse effects positions neuromodulation as an especially attractive option for children with complex medical histories, polypharmacy, or high risk for medication overuse headache[161].

In addition to the established devices above, newer approaches are under investigation, including combined occipital and trigeminal stimulation systems, wearable, on-demand neuromodulation platforms, and personalized stimulation dosing based on real-time neurophysiologic feedback. As pediatric-specific RCT data accrue, neuromodulation is poised to become a mainstream component of comprehensive, mechanism-based migraine care[162].

FUTURE DIRECTIONS AND CONCLUSIONS

Toward precision medicine in pediatric migraine

The future of pediatric migraine care lies in moving beyond symptom-based algorithms toward precision medicine frameworks that integrate biological vulnerability, neurodevelopmental stage, and clinical phenotype. Advances in several domains hold particular promise[163].

Biomarker discovery: Emerging data suggest that a combination of genetic susceptibility markers, functional and structural neuroimaging signatures, and circulating neuropeptides, particularly CGRP and related inflammatory mediators, may help stratify children according to migraine subtype, treatment responsiveness, and risk of chronification. Polygenic risk scores, mitochondrial markers, and ion-channel variants are increasingly recognized as contributors to early-onset and refractory disease[164].

Phenotype-driven treatment selection: Rather than a “one-size-fits-all” escalation model, future care pathways will likely tailor therapy based on dominant mechanisms, such as sensory hypersensitivity, autonomic dysfunction, cortical hyperexcitability, or trigeminovascular predominance. For example, children with prominent aura or visual sensitivity may benefit more from neuromodulation targeting cortical excitability, whereas those with high inflammatory or CGRP-driven phenotypes may respond more robustly to CGRP-targeted therapies as pediatric evidence matures[165]. Ultimately, precision medicine in pediatric migraine aims to optimize efficacy while minimizing unnecessary medication exposure during critical periods of brain development.

Understanding and harnessing the placebo effect

One of the most striking features of pediatric migraine research is the consistently high placebo response rate, which has historically complicated clinical trials but offers valuable insights into neurobiology and clinical care[166].

Neurobiological basis: Neuroimaging and experimental studies suggest that children exhibit heightened activation of expectation-related neural networks, including prefrontal-limbic circuits involved in reward, learning, and pain modulation. These networks interact closely with descending inhibitory pathways, providing a biological substrate for robust placebo responsiveness[167].

Implications for trial design: Recognizing this effect is essential to pediatric trial methodology, which necessitates larger sample sizes, innovative trial designs, and the use of objective or functional outcome measures. Importantly, a high placebo response does not negate treatment efficacy; rather, it underscores the developing brain’s sensitivity to contextual and relational factors[168].

Clinical translation: In routine practice, the placebo effect should not be viewed as a confounder but as a therapeutic ally. Clear communication, validation of the child’s experience, structured treatment plans, and family engagement can significantly enhance outcomes by activating endogenous pain-modulating systems, particularly when combined with mechanism-based therapies[169].

Clinical implications

Pediatric migraine is best understood not as a smaller or incomplete version of adult migraine, but as a distinct neurodevelopmental disorder with age-specific mechanisms, phenotypes, and therapeutic needs. Its manifestations reflect the dynamic maturation of sensory processing, autonomic regulation, and cortical excitability across childhood and adolescence[170].

This evolving understanding carries several critical clinical imperatives. Early and accurate diagnosis: Prompt recognition, particularly of migraine equivalents and atypical presentations, can prevent years of misdiagnosis, unnecessary investigations, and avoidable disability[171]. Mechanism-based therapy: Treatment selection should align with the dominant biological and developmental drivers of each child’s disease and integrate pharmacologic, behavioral, and device-based strategies[172]. Multidisciplinary, individualized care: Optimal management requires collaboration among pediatricians, neurologists, psychologists, school systems, and families, recognizing that migraine affects academic performance, emotional health, and quality of life[173].

As therapeutic options expand, from CGRP-targeted agents to neuromodulation and digital health interventions, the challenge ahead is not a lack of tools, but the thoughtful integration of these tools into personalized, developmentally informed care pathways. Addressing pediatric migraine early and comprehensively offers a unique opportunity to alter disease trajectory and reduce lifelong burden, transforming outcomes well beyond childhood[174].

Prioritized research agenda

To bridge the current evidence gap, the following areas require urgent investigation. Pediatric-specific RCTs: Dedicated trials for gepants and ditans in children < 12 years to move beyond adult extrapolation. Long-term safety cohorts: Prospective tracking of CGRP-blockade impacts on pubertal development and bone density over 5-10 years. Real-world outcome metrics: Transitioning from “headache days” to functional endpoints such as school absenteeism, presenteeism, and pediatric quality of life. Bio-behavioral synergy: Studies evaluating the additive effect of neuromodulation combined with CBT as a first-line non-pharmacologic “bundle”.

Limitations of the review

This review has several important limitations that should be acknowledged. First, as a narrative and mechanistic synthesis, it does not follow a formal systematic review or meta-analytic methodology. Although the literature was selectively curated to emphasize high-quality trials, consensus statements, and biologically informative studies, the potential for selection bias cannot be fully excluded.

Second, the pediatric migraine evidence base remains uneven, particularly for newer therapeutic classes such as CGRP-targeted agents, gepants, ditans, and neuromodulation devices. Much of the available pediatric data derives from open-label studies, subgroup analyses, or extrapolation from adult populations. As a result, some mechanistic inferences and clinical recommendations, while biologically plausible, may evolve as ongoing randomized pediatric trials mature.

Third, migraine is a heterogeneous disorder across developmental stages, and the age ranges encompassed within pediatric studies (infancy through late adolescence) are broad. Many clinical trials and observational cohorts do not stratify outcomes by pubertal status, sex hormones, or neurodevelopmental milestones, limiting the precision with which developmental mechanisms can be linked to clinical phenotypes.

Fourth, although this review integrates emerging concepts such as cortical excitability, trigeminovascular maturation, and placebo neurobiology, validated biomarkers that can guide individualized treatment decisions in children remain lacking. Consequently, the proposed precision-medicine framework remains aspirational rather than fully implementable in current routine practice. Finally, long-term safety data, particularly regarding chronic preventive therapies initiated during critical periods of brain development, are limited. This is especially relevant for biologic agents and centrally acting neuromodulatory approaches, underscoring the need for extended post-marketing surveillance and longitudinal pediatric cohorts.

CONCLUSION

Pediatric migraine is a developmentally dynamic neurological disorder, shaped by the maturation of cortical excitability, sensory filtering, autonomic regulation, and pain modulatory networks. Its clinical expression, ranging from episodic syndromes in early childhood to classic migraine phenotypes in adolescence, reflects an evolving brain rather than a truncated adult disease model.

Advances in mechanistic understanding have reframed pediatric migraine as a disorder of neurodevelopmental vulnerability, providing a coherent framework to explain age-specific features such as bilateral pain, shorter attack duration, prominent autonomic symptoms, and high placebo responsiveness. These insights also illuminate why early intervention is critical, not only for symptom relief but for preventing central sensitization and long-term chronification.

Therapeutically, management is transitioning from empiric, adult-derived strategies toward mechanism-based, individualized care, integrating lifestyle optimization, behavioral interventions, pharmacologic therapies, neuromodulation, and, emerging on the horizon, targeted CGRP-based treatments. Equally important is the recognition that family engagement, expectation management, and school-based support are not ancillary, but central components of effective care.

Looking forward, progress in pediatric migraine will depend on developmentally informed clinical trials, biomarker discovery, and ethically grounded long-term safety studies. By embracing a precision-oriented, multidisciplinary approach, clinicians have a unique opportunity to alter disease trajectory early in life, reducing lifelong burden and improving neurological health well beyond childhood.